CALLENTIS CONSULTING GROUP LLC

Biotech

AI-based drug discovery platform using graph neural networks to identify molecular targets and candidate compounds for substance use disorder treatment

Grants
$694K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · High-performance BPA-free dental restoration composites with remineralization capabilities$295,689
Federal grantDepartment of Health and Human Services · Phase I · AI Platform to Discover Therapeutics for Substance Use Disorders$397,829
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2326APT THERAPEUTICS, INC.——
2327Landos Biopharma—$60M
2328RESVITA BIO, INC.——
2329CALLENTIS CONSULTING GROUP LLC——
2330Protein Dynamic Solutions, Inc.—$3.4M
2331GlycoEra——
2332Secura Bio, Inc.—$50M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.